90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II study is aimed at the clinical efficacy and toxicity of 6th R-CHOP chemotherapy
followed by ibritumomab tiuxetan (Zevalin) consolidation in patients with limited-stage,
bulky diffuse large B cell lymphoma (DLBCL).
Phase:
Phase 2
Details
Lead Sponsor:
Chonnam National University Hospital
Collaborators:
Asan Medical Center Chonbuk National University Hospital Dong-A University Hospital Pusan National University Hospital Samsung Medical Center Severance Hospital